Attenuation-Corrected vs. Nonattenuation-Corrected 2-Deoxy-2-[F-18]fluoro-d by Hoekstra, Otto et al.
B Academy of Molecular Imaging, 2007
Published Online: 21 February 2007 DOI: 10.1007/s11307-007-0076-5
Mol Imaging Biol (2007) 9:99Y105
REVIEW ARTICLE
Attenuation-Corrected vs. Nonattenuation-
Corrected 2-Deoxy-2-[F-18]fluoro-D-glucose-
Positron Emission Tomography in Oncology,
A Systematic Review
Urvi Joshi,1 Pieter G. H. M. Raijmakers,1,4 Ingrid I. Riphagen,2 Gerrit J. J. Teule,3
Arthur van Lingen,1 Otto S. Hoekstra1
1Department of Nuclear Medicine and PET Research, VU University Medical Centre, 1117 De Boelelaan, 1081 HV, Amsterdam,
The Netherlands
2Medical Library, Vrije Universiteit, Amsterdam, The Netherlands
3Department of Nuclear Medicine, Academic Hospital Maastricht, Maastricht, The Netherlands
4Department of Epidemiology and Biostatistics, VU University Medical Centre, Amsterdam, The Netherlands
Abstract
Purpose: To perform a systematic review and meta-analysis to determine the diagnostic
accuracy of attenuation-corrected (AC) vs. nonattenuation-corrected (NAC) 2-deoxy-2-[F-18]
fluoro-D-glucose-positron emission tomography (FDG-PET) in oncological patients.
Procedures: Following a comprehensive search of the literature, two reviewers independently
assessed the methodological quality of eligible studies. The diagnostic value of AC was studied
through its sensitivity/specificity compared to histology, and by comparing the relative lesion
detection rate reported with NAC-PET vs. AC, for full-ring and dual-head coincidence PET (FR-
and DH-PET, respectively).
Results: Twelve studies were included. For FR-PET, the pooled sensitivity/specificity on a
patient basis was 64/97% for AC and 62/99% for NAC, respectively. Pooled lesion detection
with NAC vs. AC was 98% [95% confidence interval (95% CI): 96Y99%, n=1,012 lesions] for FR-
PET, and 88% (95% CI:81Y94%, n=288 lesions) for DH-PET.
Conclusions: Findings suggest similar sensitivity/specificity and lesion detection for NAC vs. AC
FR-PET and significantly higher lesion detection for NAC vs. AC DH-PET.
Key words: Deoxyglucose (MeSH), Tomography, X-ray computed (MeSH), Tomography,
emission-computed (MeSH), Neoplasms (MeSH), Human (MeSH), Systematic review (MeSH),
Attenuation correction, Positron emission tomography
Introduction
The attenuation of photons originating from the subjectbefore they are detected by the camera is a generic
limitation of nuclear medicine imaging. This attenuation
can lead to image distortion and impairs adequate quanti-
fication. Attenuation correction has been commonly
employed in 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) im-
aging in an attempt to correct for these effects. With
positron emission tomography (PET) scanners, this is
accomplished by transmission scanning using a radionuclide
source, such as germanium-68 or cesium-137, and with
PET/computed tomography (CT) using CT. With respect to
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visual interpretation of the images, the added value of
attenuation correction has been controversial. Whereas
attenuation correction provides a more realistic image of
FDG distribution, its application significantly increases
acquisition times on standard full-ring (FR) PET scanners.
In addition, the performance of attenuation correction can
introduce noise and even artifact. Paradoxically, even if the
nuclear medicine community sees attenuation correction, or
the lack of it, as a potential effect-modifier of test accuracy,
its impact is rarely accounted for in systematic reviews on
the diagnostic accuracy of PET. As a result, the impact of
attenuation correction on lesion detectability and interpre-
tation of PET for oncological purposes is not well
established. With PET/CT scanning, it is customary to
evaluate either modality (primarily to account for artifacts),
but one needs to know how to deal with discrepancies.
The objective of this systematic review and meta-
analysis was to determine the diagnostic accuracy of
nonattenuation-corrected (NAC) and attenuation-corrected
(AC) FDG-PET in oncological patients. We studied the
effects of attenuation correction for both FR-PET and dual-
head coincidence PET (DH-PET), and as a function of
different body locations (head/neck, chest, abdomen/pelvis).
Materials and Methods
Literature Search
A computer-aided literature search was performed in both Medline
and Embase databases without time range or language restrictions,
applying controlled vocabulary (MeSH and EMTREE keywords,
respectively) as well as free text words. The search date was
February 10, 2006. The search strategy (Appendix) included terms
for PET with FDG, modified from Mijnhout et al. [1] as well as
search terms identifying both radionuclide and X-ray transmission,
emission, attenuation correction, and oncological studies in
humans. In addition, the reference lists of the eligible articles
were reviewed to ensure that relevant articles had not been missed.
Study Selection
From the list of retrieved articles, articles were initially evaluated
for eligibility on the basis of title and abstract by two independent
reviewers (UJ, PR). If there was uncertainty as to whether an
article was eligible for inclusion, the entire article was reviewed.
Inclusion criteria were (1) clinical studies evaluating FDG imaging
with and without attenuation correction in oncology patients; (2)
study population of at least ten patients; (3) sufficient detail to
reconstruct a 22 contingency table expressing FDG imaging
results by disease status, or sufficient detail to reconstruct relative
lesion detection measurement of AC vs. NAC imaging; and (4)
studies utilizing FR-PET and/or DH-PET. We excluded abstracts,
editorials, and reviews, although the latter two categories were
used for cross-referencing.
Methodological Quality Assessment
The methodological quality of each article was independently
assessed by each reviewer in terms of internal and external validity
(Table 1), based on the Cochrane Methods Group in Screening and
Diagnostic Tests, modified for our area of interest [2]. Internal
validity items focus on whether a valid reference test was used and
whether this reference test was uniformly and independently
applied and interpreted as well the type of study design. The
external validity items evaluate the applicability of the results in
terms of the type of patient population and spectrum, demograph-
ics, the inclusion/exclusion criteria, the knowledge of previous
test/clinical information that could influence interpretation, and the
index test characteristics. Items were scored as positive, negative,
or unclear.
Data Extraction and Quantitative
Analysis
In addition to methodological quality assessment, data
related to the type of camera, the FDG dose, the time
interval between injection and imaging, the transmission
and emission acquisition protocols, the reconstruction
protocol, and the interpretation protocol were independently
Table 1. Methodological assessment of individual diagnostic studies: criteria
Test Criteria
A. Internal study validity
Al. Valid reference test Histology, AC FR or DH coincidence PET
A2. Blind measurement of reference test(s) without knowledge of index test Assessment of reference test independent of index test(s) results
A3. Avoidance of verification bias Choice of patients assessed by reference test independent of index
test result
A4. Index test(s) interpreted independently of all clinical information Mentioned in publication
A5. Prospective study Mentioned in publication
B. External study validity
B1. Spectrum of diseases Localization of disease described (selected or general)
B2. Demographic information Age and sex given
B3. Inclusion criteria described Mentioned in publication
B4. Exclusion criteria described Mentioned in publication
B5. Avoidance of selection bias Consecutive series of patients
B6. Standardized execution of index test(s) Described technical aspects of index test(s)
C. Reproducibility described Mentioned in publication
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extracted from each study by each reviewer. For studies
where it was possible, a contingency 22 table was
constructed. Disagreements were solved by consensus.
For studies using an independent gold standard (histopa-
thology), we determined the sensitivity and specificity of
the index tests using the number of true positive, false
positive, true negative, and false negative results from the
22 contingency table. Furthermore, we calculated the
Brelative lesion detection,^ defined as the percentage of
lesions scoring equally positive or negative with NAC vs.
AC images. We performed a subgroup analysis for different
locations of lesions and analyzed sensitivity, specificity, or
relative lesion detection of NAC vs. AC for lesion location
in the head and neck region, the chest, and the abdomi-
nopelvic region. In cases of discrepancy of relative lesion
detection between NAC and AC, we extracted data to
analyze whether this was related to lesion size and/or
intensity.
The statistical diagnostic heterogeneity of the sensitivity
and specificity per index test across studies was tested by
the chi-square test. In case of statistical heterogeneity of
DH- or FR-FDG-PET imaging, a random effect model for
pooling was used, whereas in case of statistical homogene-
ity, a fixed-effect model was used. Sensitivity, specificity,
and relative lesion detection were pooled independently, all
pooled estimates are presented with 95% confidence
intervals (95% CI). The logit transformed sensitivity,
specificity, relative lesion detection, and corresponding
95% CI of the index tests were compared using z-test
statistics. A p value of less than 0.05 was considered
significant.
All statistical analyses were performed with the SPSS
11.0.01 program for Windows (version 11.0.1., SPSS,
Chicago, IL, USA).
Results
The search strategy yielded 2,202 references, 1,477 in
Medline and 725 in Embase on February 10, 2006. Of the
Embase references, 370 were also included in Medline,
leaving a total of 1,832 unduplicated references. On the
basis of title and abstract alone, 1,806 references were
excluded. After review of the full text of the remaining 26
articles, an additional 11 studies [3Y12] proved to be
ineligible because they did not perform a direct comparison
of the yield of NAC vs. AC images in oncological patients.
One study [13] was excluded because it was published in
abstract form only. Another study [14] was excluded
because it was published in Japanese and was not readily
translatable. Finally, the study of Hustinx et al. [15], who
evaluated the effect of attenuation correction in abdominal
tumors for a sodium iodide crystal (NaI) PET scanner, was
excluded because no 22 contingency tables could be
constructed. Eventually, we included 12 studies for review
[16Y27].
A summary of the methodological quality assessment
results can be found in Table 2. Methodological quality was
scored as negative when quality items were unclear or
absent in the original article. In a minority (4/12=33%) of
studies, histology served as the reference test. However,
nine of the 12 studies provided a direct comparison of AC
and NAC PET. In three studies, blind measurement of
reference test was performed without knowledge of index
test. All but one study avoided verification bias. In four
studies, the index test(s) was evaluated independently of all
clinical information. All studies provided information about
the spectrum of diseases being evaluated and standardized
the execution of the index test(s). Almost all studies (11/
12=92%) described the demographics of the study popula-
tion and inclusion criteria. However, only one study
mentioned specific exclusion criteria. Six studies were
prospective. Only two of the 12 studies specifically
mentioned including consecutive patients, and only three
studies specifically described the reproducibility of their
results.
Meta-Analysis
Three FR-PET studies were eligible for pooling of sensi-
tivity on a patient basis [22, 24, 25]. The pooled sensitivities
for AC and NAC FR-PET were 64% (95% CI 52Y74%) and
62% (95% CI 51Y73%), respectively (n=182 patients). Two
FR-PET studies provided data that allowed pooled analysis
of specificity [22, 24]. Weber et al. [25] could not be
Table 2. Quality assessment of included studies
Study Year A1 A2 A3 A4 A5 B1 B2 B3 B4 B5 B6 C
Bleckmann 1999 + + + + j + j + j j + j
Chan 2001 + j + j j + + + j j + j
Delbeke 2001 + j + j + + + + j j + j
Even-Sapir 2004 + j + j + + + + j + + j
Kotzerke 1999 + j + j j + + + j + + +
Lonneux 1999 + j + j + + + j j + + +
Nakamoto 2002 + + + + + + + + j j + +
Reinhardt 2005 + j + j j + + + + j + j
Schauwecker 2003 + j j j j + + + j j + +
Weber 1999 + j + j + + + + j j + j
Zimny 1999 + + + + j + + + j j + j
Zimny 2003 + j + + + + + + j j + j
U. Joshi, et al.: AC vs. NAC FDG-PET in Oncology 101
included as there were no patients without disease. The
pooled specificities for AC and NAC FR-PET were 97%
(95% CI 92Y99%) and 99% (95% CI 95Y100%), respec-
tively (n=155 patients). For DH-PET, only one study
provided data on sensitivity and specificity [27].
Relative lesion detection for NAC vs. AC PET was
pooled for 11 studies, which are demonstrated in Fig. 1.
Lesion detection of NAC FR-PET vs. AC FR-PET was 98%
(95% CI: 96Y99%) for n=1,012 lesions (pooling of n=7
studies); 79% of which were classified FDG positive at AC
FR-PET. Lesion detection of NAC DH-PET vs. AC DH-
PET was 88% (95% CI: 81Y94%) for n=288 lesions
(pooling of n=4 studies); 74% of which were classified as
FDG-positive at AC DH-PET.
In addition, we evaluated the relative lesion detection
depending on body location (head/neck, chest, abdomen/
pelvis) in the four FR-PET [20, 21, 23, 26] and in the three
DH-PET studies that provided sufficiently detailed infor-
mation [17, 18, 26]. The relative sensitivity and specificity
based on body location could not be calculated due to an
insufficient number of studies. For FR-PET, we found
similar relative lesion detection for the three body locations:
95% for head/neck (95% CI 84Y98%, n=61 lesions), 97%
for the chest (95% CI 94Y99%, n=396 lesions), and 97% for
the abdomen/pelvis (95% CI 93Y0.99%, n=205 lesions). For
DH-PET, relative detection rates for NAC were not
significantly different for the various body sites: 78% in
the abdomen/pelvis (95% CI 65Y88%; 53 lesions), 84% in
the chest (95% CI 74Y91%; 136 lesions), and 90% in the
head/neck area (95% CI 73Y97%; 38 lesions). However, in
chest (p=0.000089) and abdomen/pelvis (p=0.0037), the
relative detection rates with NAC (vs. AC) for DH-PET
were significantly lower than those obtained with FR-PET.
A comprehensive analysis of the potential association of
relative detection and lesion size and/or intensity, for
lesions with discrepant AC and NAC results, was not
possible due to a lack of detailed information. We
summarized the results in Table 3: findings of Bleckmann
et al. and Reinhardt et al. [16, 23] suggest that AC and NAC
discrepancies may relate to (intrapulmonary) lesion size
with more discrepancies occurring with smaller lesions at
the subcentimeter level (an average of 3% of lesions were
correctly detected with NAC and not with AC). The single
discrepant lesion in the study of Weber et al. concerned a
G1-cm lesion in the mediastinum [25]. However, the
discrepant lesions in the studies of Nakamoto et al.,
Schauwecker et al., and Delbeke et al. included both small-
and moderate-sized lesions (in relation to lesions included
each study) [18, 22, 24]. In the study of Schauwecker et al.,
the discrepant lesions demonstrated SUVmax values rang-
Fig. 1. Pooled lesion detection of NAC vs. AC images for FR-PET and DH-PET.
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ing from 1.8 to 2.6, whereas, in the study of Delbeke et al.,
the two discrepant lesions demonstrated only mildly
enhanced uptake on AC images and equivocal uptake on
NAC images.
Discussion
The cumulated evidence summarized in this systematic
review of oncological FDG imaging studies suggests that
the accuracy of attenuation and nonattenuation corrected
FR-PET are similar. However, with DH coincidence
imaging NAC images detect 12% less lesions than AC
images, without prominent differences between body areas.
Although in the nuclear medicine field attenuation
correction is generally seen as an important issue, it is
surprising to find that several large systematic reviews did
not thoroughly consider this as a potential effect-modifier.
Gould et al. performed systematic reviews on FDG PET in
pulmonary lesions [28] and mediastinal lymph node staging
in non-small cell lung cancer [29]: in the former review, the
item was not mentioned, and in the latter, attenuation
correction was an item of study quality, but no analysis of
potential impact was performed.
The choice of the reference test is obviously relevant in
studies on test accuracy. In oncology, histopathology is the
typical endpoint. Of the 12 eligible studies, four used
histology as an independent gold standard. Meta-analysis of
sensitivity and specificity was only possible for FR-PET,
and we found no significant difference for either measure.
We chose to use the AC detection rate as an alternative
reference test, which defines the relative lesion detection of
NAC vs. AC images. This choice theoretically biases in
favor of AC: Bleckmann et al. and Reinhardt et al. [16, 23]
reported an average of 3% more true positive lesions with
NAC FR-PET. However, we expect that the resulting error
is small because, in the comparison with histopathology,
false positive rates were quite low for either modality.
Despite this theoretical negative bias towards NAC, similar
lesion detection rates were observed with both AC and NAC
for FR-PET. Hence, attenuation correction may not con-
tribute to the detection of malignancy using FR-PET.
Conversely, with DH-PET, AC images demonstrated a
significantly higher detection rate as opposed to NAC
images, which is surprising given that AC images are
usually significantly noisier than NAC images. We postulate
that this may be secondary to differences in reconstruction/
filtering algorithms.
In addition, there are limitations associated with
performing a meta-analysis and data pooling, such as the
homogeneity of the data and the quality of the published
studies. Homogeneous data have higher statistical strength
than heterogeneous data. The data in our study were
heterogeneous so that we used a random effect model for
pooling. In addition, the statistical strength of the meta-
analysis is limited by the quality of the published studies
included in it. As mentioned earlier and summarized in Table
2, the studies had several quality limitations. Finally, meta-
analyses are limited by publication bias, which biases
towards the publication of favorable results or popular
subjects.
We were surprised by the limited number of good
comparative studies evaluating the value of attenuation
correction. It appears that attenuation correction has been
accepted as the standard of practice without sound scientific
evidence to support it.
The introduction of PET/CT machines has made the time
constraints associated with transmission scanning less of an
issue. However, PET/CT is not a panacea; X-ray transmis-
sion scanning has its own problems and numerous PET/CT
publications have demonstrated artifact that can be intro-
duced with X-ray transmission scanning [5, 30Y45].
Furthermore, in the study of Reinhardt et al. [23], a
significantly improved visibility was demonstrated for
41% of lung metastases with NAC images as opposed to
CT-AC images. This higher visibility for NAC images was
even more pronounced for lesions smaller than 1 cm. These
findings underline that even as PET/CT use becomes more
widespread, evaluation of both NAC and AC images should
remain an integral part of image interpretation, and not just
to recognize image artifacts. At the same time, NAC vs. AC
discrepancies at PET/CT offer an obvious opportunity for
further investigation.
Conclusions
In this meta-analysis, we found no significant difference in
sensitivity, specificity, or relative lesion detectability be-
tween AC and NAC FR FDG PET. However, attenuation
Table 3. Evaluation of discrepant lesions between AC and NAC images with respect to lesion size and intensity
Study Camera type Number of discrepant lesions Size range Intensity (semiquantitative or qualitative)
Bleckmann et al. FR-PET 5 G1 cm Not given
Nakamoto et al.a FR-PET 1 1.8 cm Not given
Reinhardt et al. FR-PET 6 0.5Y1.1 cm 79/174 lesions demonstrated discrepancy in qualitative lesion
intensity: 72/174 lesions demonstrating higher intensity
(i.e., better visibility) on NAC images
Schauwecker et al.a FR-PET 4 0.8Y3.9 cm3 1.8Y2.6 (SUVmax)
Weber et al. FR-PET 1 0.8 cm Not given
Delbeke et al. DH-PET 2 1.0Y3.0 cm BMild uptake^ at AC, Bequivocal uptake^ at NAC
aHistology used as gold standard and detailed information given only for true positive lesions
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correction improved lesion detection for DH coincidence
imaging.
Appendix
Detailed search strategy
(Bx ray^ OR x-ray OR cine-ct OR BTomography, X-Ray Computed^
[mesh] OR transmission OR attenuat* OR nonattenuat* OR ac[tw] OR nac
[tw] OR nonac OR germanium OR ge[tw] OR gallium OR ga[tw] OR
cesium OR cs[tw]) AND (oncolog* OR cancer* OR neoplas* OR neo-
plasms[mesh] OR tumor* OR tumor OR tumors OR carcinom* OR melanom*
OR lymphom* OR malignan*) AND (Deoxyglucose[mesh] OR Deoxyglu-
cose[tw] OR Desoxyglucose[tw] OR Desoxy-glucose[tw] OR deoxy-glucose
[tw] OR Deoxy-d-glucose[tw] OR Desoxy-d-glucose[tw] OR fluorodeoxy-
glucose[tw] OR Fluorodesoxyglucose[tw] OR fluorodeoxy-glucose[tw]
OR Fluorodeoxy-d-glucose[tw] OR Fluoro-d-glucose[tw] OR Fludeoxy
glucose[tw] OR Fluordeoxyglucose[tw] OR Fluordesoxyglucose[tw] OR
18fluorodeoxyglucose[tw] OR 18fluorodeoxy-glucose OR 18fluorodesoxy
glucose[tw] OR 18Fluordeoxyglucose[tw] OR fdg*[tw] OR 18fdg*[tw]
OR 18f-dg*[tw] OR 2deoxyglucose[tw] OR 2deoxy-d-glucose[tw] OR
((fluor[tw] OR fluoro[tw] OR 18fluor[tw] OR 18fluoro[tw]) AND
glucose[tw])) AND (pet[tw] OR pet/* OR petscan* OR BTomography,
emission-computed^ [mesh] OR (positron[tw] AND emission[tw] AND
tomograph*[tw]) OR (emission[tw] AND computed[tw] AND tomog-
raph*[tw])) NOT (animal [mesh] NOT human[mesh])
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